Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Anti-C5a Antibody BDB-001 for Severe COVID-19: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Clinical Trial in Healthy Chinese Adults

INTRODUCTION: Severe Coronavirus Disease 2019 (COVID-19) progresses with inflammation and coagulation, due to an overactive complement system. Complement component 5a (C5a) plays a key role in the complement system to trigger a powerful “cytokine and chemokine storm” in viral infection. BDB-001, a r...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Guiling, Li, Nan, Dai, Xiahong, Tu, Shiyan, Shen, Zhenwei, Wu, Kaiqi, Jin, Tinghan, Wu, Jiajun, Peng, Conggao, Sheng, Guoping, Zhu, Mengfei, Tang, Lingling, Li, Lanjuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9876408/
https://www.ncbi.nlm.nih.gov/pubmed/36697937
http://dx.doi.org/10.1007/s40121-023-00759-4

Ejemplares similares

Ejemplares similares